Bird & Bird wins for Neuraxpharm in proceedings against Biogen over MS drug

International law firm Bird & Bird wins for Neuraxpharm in German court proceedings against Biogen over Multiple Sclerosis (‘MS’) drug.

The Regional Court Düsseldorf announced a judgment rejecting the request for preliminary injunction (‘PI’) against sales of Neuraxpharm’s generic MS pharmaceutical “Dimethylfumarate Neuraxpharm” in Germany. The PI request filed by Biogen MA, Inc. (“Biogen”) was based on the allegation that the marketing of “Dimethylfumarate Neuraxpharm” in Germany would infringe the German part of the European Patent EP 2 653 873 B1 (“EP’873”).

Based on presented evidence, the Regional Court held that Biogen failed to establish a ground for the grant of the requested PI. In its judgment rejecting the PI request, the Regional Court Düsseldorf questioned the validity of EP’873 and considered it more likely that EP’873 will be revoked for lack of inventive step in the pending EPO opposition proceedings than that it will be upheld. In this regard, the Regional Court assumed that the daily dosage of 480 mg DMF was not inventive.

Biogen has appealed the judgment, however, the team are optimistic that this decision will be upheld and that it will favourably impact similar PI proceedings filed by Biogen in various other countries against the sale of “Dimethylfumarate Neuraxpharm” on the basis of EP’873. The Bird & Bird team was led by Dr. Matthias Meyer (partner, Intellectual Property) and Dr. Daniel Misch (counsel, Intellectual Property) and was completed by Dr. Ingo Ortel and Dr. Bernd Aechter (both of the patent attorney firm Ter Meer Steinmeister, Munich).

Dr. Matthias Meyer, Intellectual Property partner at Bird & Bird, says: “We are very pleased to have been able to advise Neuraxpharm in this landmark case against Biogen. It is particularly good news that we have been able to help Neuraxpharm stay in the German market, even though original manufacturers are often victorious in patent infringement cases”.

News & Deals

More News & Deals

Deal

Bird & Bird advises Arm as a cornerstone investor in Raspberry Pi’s London IPO

Jun 25 2024

Read More

News

Bird & Bird and OXYGY announce together with the European Commission and Warren Brandeis the publication of the best practices report 2024 for the European Blockchain Sandbox

Jun 20 2024

Read More

News

Bird & Bird ATMD advised Korea Investment Partners (KIP) on its strategic investment in LiveIn

Jun 19 2024

Read More

Deal

Bird & Bird advised Patria on its acquisition of Nordic Drones

Jun 17 2024

Read More

Deal

Bird & Bird advises Hydrogen Dynamo on the sale of Fjorden Electra to Leica Camera

Jun 14 2024

Read More

News

Bird & Bird and OXYGY announce together with the European Commission 20 use cases selected for second cohort of European Blockchain Sandbox

Jun 13 2024

Read More